Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
基本信息
- 批准号:10681470
- 负责人:
- 金额:$ 63.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-10 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS clinical trial groupAntibodiesAuthorization documentationBehavioralBiological AssayBiological AvailabilityBloodBrainCOVID-19CXCL10 geneCellsCentral Nervous SystemCerebrospinal FluidClinicClinicalDNADataDoseDrug KineticsEmergency SituationEncephalitisFDA approvedFutureGeneticGoalsHIVHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsIL7 geneImmunologic MarkersIn VitroIndividualInfectionInterleukin-15InterventionJanus kinaseLightLinkLongevityMacaca mulattaMagnetic Resonance ImagingMental DepressionMicrotubule-Associated Protein 2ModelingMorbidity - disease rateMyelofibrosisNeopterinNeurocognitive DeficitNeuronsNeuropsychologyOpportunistic InfectionsOralParticipantPerformancePeripheralPersonsPharmaceutical PreparationsPhasePlacebosPolycythemia VeraPropertyPublishingRNARandomizedRegimenRenal clearance functionReportingResearchRetroviridae InfectionsRheumatoid ArthritisRiskSafetySiteSourceSpectrum AnalysisTestingTherapeuticVirusVirus DiseasesWorkantiretroviral therapyauthoritybrain parenchymabrain tissuecytokinedepressive symptomsefficacy evaluationimmune activationimprovedin vivoinflammatory markerinhibitorinhibitor therapyinnovationmembermortalitymouse modelneurofilamentneuroprotectionnovelphase 2 studyphase 3 studyphenotypic biomarkerpre-clinicalpreferencerandomized placebo controlled studyside effectsocial stigmasymposium
项目摘要
Project Summary/Abstract
Although HIV infection is controllable with antiretroviral therapy (ART), HIV cure continues to be
extremely elusive. Cure of HIV is desperately needed for many reasons. People with HIV (PWH) have persistent
increases in morbidity and mortality despite ART, and while newer ART agents have become better tolerated,
they are still associated with multiple side effects. Having to attend HIV clinics and take ART over the long term
still carries significant stigma for PWH. Additionally, many PWH have a preference for cure rather than a lifetime
of ART, and some would take significant risks to achieve a cure. For all of these reasons, finding a cure for HIV
is one of the ultimate goals of the field.
There is a large and growing body of evidence that the central nervous system (CNS) is an HIV reservoir
site that represents another barrier to HIV eradication. HIV DNA is commonly found in brain tissue from PWH on
suppressive ART, and there are multiple published reports of CNS virologic escape. Multiple studies, including
from our group, have demonstrated that HIV RNA can be detected at very low levels in CSF during suppressive
ART and that anti-HIV antibodies are also present in the CSF among individuals on ART. New members of our
group recently presented findings with an innovative assay (Double-R) to reliably quantitate HIV RNA and DNA
from CSF.
Our group has performed extensive pre-clinical and clinical work on the Janus Kinase (Jak 1/2) inhibitor
drug class to target HIV. This includes work on baricitinib, an FDA approved orally bioavailable Jak 1/2 inhibitor
for rheumatoid arthritis. We have demonstrated that baricitinb blocks HIV replication, HIV-induced activation and
infection in key CNS cells, and reservoir reseeding. In vivo, we have shown in our murine model that baricitinib
decreases CNS HIV and reverses behavioral abnormalities conferred by HIV. We have also demonstrated that
baricitinib achieves therapeutic CNS concentrations in the rhesus macaque model. We now propose to study
baricitinib as a therapy to decrease the HIV CNS reservoir in a study of PWH with durable virologic suppression
on ART. This will be a phase IIa randomized placebo controlled study. Our primary hypothesis is that individuals
randomized to baricitinib will be more likely to achieve a decrease in CSF cell associated HIV RNA and DNA by
Double-R assay. We also hypothesize that baricitinib treatment will be associated with a significant decrease in
other markers of HIV CNS persistence, including HIV-specific CSF antibodies, CSF cell associated DNA
including by Integrated Proviral DNA (IPDA), CSF RNA by single copy assay, CSF HIV Tat levels, and markers
of inflammation that have been linked to CNS HIV persistence, as well as magnetic resonance imaging and
spectroscopy markers. Additionally, we hypothesize that baricitinib treatment will be safe for the CNS as defined
by neuropsychological performance, depression symptoms, and neuronal damage. We are confident that this
study will provide a strong basis for baricitinib to be included in regimens that target eradication of HIV.
项目摘要/摘要
尽管艾滋病毒感染可通过抗逆转录病毒疗法(ART)控制,但艾滋病毒的治愈仍在继续
非常难以捉摸。出于许多原因,迫切需要治愈艾滋病毒。艾滋病毒携带者(PWH)有持续性
尽管抗逆转录病毒治疗的发病率和死亡率有所增加,但新的抗逆转录病毒药物已经变得更好地耐受,
它们仍然与多种副作用有关。必须长期去艾滋病毒诊所和参加抗逆转录病毒药物治疗
对威斯康星医院来说,这仍然是一种严重的耻辱。此外,许多PWH倾向于治愈而不是终生
一些人会冒着巨大的风险来实现治愈。出于所有这些原因,找到一种治疗艾滋病毒的方法
是该领域的终极目标之一。
越来越多的证据表明,中枢神经系统(CNS)是艾滋病毒的宿主
这是根除艾滋病毒的又一个障碍。人类免疫缺陷病毒脱氧核糖核酸通常在先天疱疹后的脑组织中发现。
抑制性艺术,并且有多个发表的关于中枢神经系统病毒学逃逸的报道。多项研究,包括
已经证明,在抑制期间,可以在脑脊液中检测到非常低水平的艾滋病毒RNA
ART和抗HIV抗体也存在于接受ART治疗的个体的脑脊液中。我们的新成员
该小组最近公布了一种创新的方法(Double-R),以可靠地量化HIV RNA和DNA
从脑脊液。
我们小组对Janus Kinase(JAK1/2)抑制剂进行了广泛的临床前和临床工作
针对HIV病毒的药物类。这包括FDA批准的口服生物可用JAK1/2抑制剂巴利替尼的研究。
治疗类风湿性关节炎。我们已经证明,巴利西丁可以阻止HIV复制、HIV诱导的激活和
关键中枢神经系统细胞的感染,以及水库的重新播种。在体内,我们已经在我们的小鼠模型中证明了巴利替尼
降低中枢神经系统HIV,逆转由HIV引起的行为异常。我们也证明了
巴利替尼在恒河猴模型中达到治疗中枢神经系统浓度。我们现在建议研究
巴利替尼作为一种治疗方法减少HIV CNS储存库,在持续病毒学抑制的PWH研究中
关于艺术。这将是一项IIa期随机安慰剂对照研究。我们的主要假设是,个人
随机服用巴利替尼将更有可能通过以下方式减少脑脊液细胞相关的艾滋病毒RNA和DNA
双R试验。我们还假设,巴利西尼治疗将与显著减少
HIV CNS持久性的其他标志,包括HIV特异性脑脊液抗体、脑脊液细胞相关DNA
包括通过整合前病毒DNA(IPDA)、通过单拷贝分析的脑脊液RNA、脑脊液HIV TAT水平和标志物
与中枢神经系统艾滋病毒持久性有关的炎症,以及磁共振成像和
光谱学标记。此外,我们假设巴利替尼治疗对中枢神经系统是安全的。
通过神经心理表现、抑郁症状和神经元损伤。我们相信,这一点
这项研究将为将巴利替尼纳入旨在根除艾滋病毒的方案提供强有力的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christina Gavegnano其他文献
Christina Gavegnano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christina Gavegnano', 18)}}的其他基金
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV
阐明肠道储存库和炎症在艾滋病毒感染者心血管疾病中的作用
- 批准号:
10548049 - 财政年份:2022
- 资助金额:
$ 63.84万 - 项目类别:
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV
阐明肠道储存库和炎症在艾滋病毒感染者心血管疾病中的作用
- 批准号:
10670393 - 财政年份:2022
- 资助金额:
$ 63.84万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 63.84万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 63.84万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 63.84万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 63.84万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 63.84万 - 项目类别:














{{item.name}}会员




